Inovio Pharmaceuticals Inc. (NASDAQ:INO) currently has a daily average trading volume of 4.58M but it saw 3156350 shares traded on Thursday. With a market cap of 299.20M USD, stock’s current market price of $1.13 came falling about -1.74 while comparing to the previous closing price of $1.15. In past 52 weeks, the stock remained buoying in the range of price level as high as $4.00 and as low as $1.09. In the recent trading on the day, stock has struck highest price mark of $1.16 while lowest mark touched by it was $1.11.
Top 5 EV Tech Stocks to Buy for 2023
According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.
Click Here to Download the FREE Report.
Sponsored
Taking a look at 20-day trading activity of Inovio Pharmaceuticals Inc. (INO) gives us an average price of $1.2650, while its current price level is -71.75% below from 52-week high level whereas it is 3.67% above from lowest level seen by the stock during that period. Simple moving average of 50 days or SMA-50 of the stock’s closing price is $1.5245 while that of 200 days or SMA-200 reads an average of $1.8564. A closer look into the stock’s movement over the week reveals that its volatility is standing at 6.82% during that period while stretching the period over a month that decreases to 6.76%. It is also necessary to take a look into other indicators of a stock too, to get a better idea about its price movement. And in doing so, we find stock’s 14-day relative strength index (RSI) standing at 32.74 which implies that the stock is in neutral territory.
Inovio Pharmaceuticals Inc. (INO)’s stock is currently under the radar of 5 analysts who are in consensus at a 12-month price target range of between $1.00 and $2.00 for company’s shares. The average price target assigned by the average number of analysts to a stock is a way to gauge worth of any stock in next 52 weeks. And in assigning price target to a stock, some analysts adopt a bearish approach by advocating lower-than-average price target which in this case is $1.00 while some adopt bullish approach by assigning higher-than-average price target which reads the price to top $2.00. Average price target assigned by them is $1.40 which highlights an upside potential of 19.29% for the stock over that period. And to attain the median price target of $1.20 assigned by those analysts, stock has to add about 5.83% of value to its current levels.
Data by FactSet Research shows that 5 analysts have issued their ratings for the stock. 0 of them are in opinions that stock is a Sell, while 0 are advising it as an Overweight. 0 analysts suggested the investors to Buy the stock while 4 advised them to Hold. Recommendations by all of those brokerages imply a consensus rating of Hold for the stock and that issued by Wall Street to investors is Hold.
BofA Securities downgraded its recommendation for the stock as a “Underperform” from “Neutral” on November 01, 2022 while assigning a price target of $2. RBC Capital Mkts issued its recommendations for the stock as it resumed the price target for the stock in the range of between $5 and $4.
Over the week, INO’s stock price is moving -1.74% down while it is -26.62% when we observe its performance for the past one month. Year-to-date it is -27.56% down and over the past year, the stock is showing a downside performance of -64.01%.
The latest quarterly earnings report issued by the company was for quarter ended 12/30/2022, when its quarterly earnings per share (EPS) of -$0.21 beaten by the consensus estimate of -$0.17 for the same. The company is expected to be releasing its next quarterly report in 05/10/2023, for which analysts forecasted an EPS of -$0.14 while estimate for next year EPS is -$0.53. For INO, analysts are forecasting an EPS-growth rate of 54.70% for current year and estimate for EPS growth in next year is 34.00%. In next quarter, company is expected to be making quarterly sales of $270k as analysts are expecting the sales for current fiscal year at $880k and seeing the company making $230k in sales next year. Moreover, analysts are in estimates of $270k for current-quarter revenue.
Currently, Inovio Pharmaceuticals Inc.’s total number of outstanding shares is 250.59M with 1.47% of that held by the insiders while 49.83% of its common stock has been owned by the institutions. Company’s return on equity (ROE) at -98.00%. Stock’s beta reads 1.14. Stock has a price to book (P/B) ratio of 1.27 while price to sale or P/S ratio amounts to 29.05. Its return on asset (ROA) is -68.00% on average.
A filing at the U.S. Securities and Exchange Commission revealed that SPDR S&P Biotech ETF came shrinking its share ownership by -0.88% in the Inovio Pharmaceuticals Inc. (INO) decreasing its stake to 8.73% with control over -0.19 million shares in the company. In the most recent quarter, iShares Russell 2000 ETF came cutting its stake by -0.32% in the company and now holds 5.51 million or 2.21% of the company’s stake having worth of about 6.95 million.
